Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results
作者： Thomas Semrad , Afsaneh Barzi , Heinz-Josef Lenz , Irene M. Hutchins , Edward J. Kim
DOI: 10.1007/S10147-014-0730-2
关键词:
摘要: … a substantially more promising result from pharmacodynamic separation with further accrual. … In conclusion, we observed no indication that pharmacodynamic separation of gemcitabine …
core.ac.uk
elsevier.com
philpapers.org
springer.com
sci-hub.se 参考文章(18)
Gilda da Cunha Santos, Neesha Dhani, Dongsheng Tu, Kayu Chin, Olga Ludkovski, Suzanne Kamel‐Reid, Jeremy Squire, Wendy Parulekar, Malcolm J Moore, Ming Sound Tsao, None, Molecular Predictors of Outcome in a Phase 3 Study of Gemcitabine and Erlotinib Therapy in Patients With Advanced Pancreatic Cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3 Cancer. ,vol. 116, pp. 5599- 5607 ,(2010) , 10.1002/CNCR.25393
Heidi Schwarzenbach, Dave S. B. Hoon, Klaus Pantel, Cell-free nucleic acids as biomarkers in cancer patients Nature Reviews Cancer. ,vol. 11, pp. 426- 437 ,(2011) , 10.1038/NRC3066
Angela M. Davies, Cheryl Ho, Laurel Beckett, Derick Lau, Sidney A. Scudder, Primo N. Lara, Natasha Perkins, David R. Gandara, Intermittent Erlotinib in Combination with Pemetrexed: Phase I Schedules Designed to Achieve Pharmacodynamic Separation Journal of Thoracic Oncology. ,vol. 4, pp. 862- 868 ,(2009) , 10.1097/JTO.0B013E3181A94B08
H. Chen, H. Tu, Z.Q. Meng, Z. Chen, P. Wang, L.M. Liu, K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer Ejso. ,vol. 36, pp. 657- 662 ,(2010) , 10.1016/J.EJSO.2010.05.014
Kurt Grünewald, John Lyons, Anja Fröhlich, Hans Feichtinger, Richard A. Weger, Gerhard Schwab, Johannes W. G. Janssen, Claus R. Bartram, High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas International Journal of Cancer. ,vol. 43, pp. 1037- 1041 ,(1989) , 10.1002/IJC.2910430614
Christopher M. Mahaffey, Angela M. Davies, Jr Primo N. Lara, Brandi Pryde, William Holland, Philip C. Mack, Paul H. Gumerlock, David R. Gandara, Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation Clinical Lung Cancer. ,vol. 8, pp. 548- 553 ,(2007) , 10.3816/CLC.2007.N.041
Randeep Sangha, Angela M. Davies, Primo N. Lara, Philip C. Mack, Laurel A. Beckett, Paul J. Hesketh, Derick Lau, Tianhong Li, Natasha Perkins, David R. Gandara, Intercalated Erlotinib-Docetaxel Dosing Schedules Designed to Achieve Pharmacodynamic Separation: Results of a Phase I/II Trial Journal of Thoracic Oncology. ,vol. 6, pp. 2112- 2119 ,(2011) , 10.1097/JTO.0B013E31822AE061
Alberto Bardelli, Salvatore Siena, Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer Journal of Clinical Oncology. ,vol. 28, pp. 1254- 1261 ,(2010) , 10.1200/JCO.2009.24.6116
Vincent T.H.B.M. Smit, Angelina J.M. Boot, Alida M.M. Smits, Gert Jan Fleuren, Cees J. Cornelisse, Johannes L. Bos, KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Research. ,vol. 16, pp. 7773- 7782 ,(1988) , 10.1093/NAR/16.16.7773
Rodolfo Marchese, Alessandra Muleti, Patrizio Pasqualetti, Barbara Bucci, Antonio Stigliano, Ercole Brunetti, Monica De Angelis, Gianluca Mazzoni, Adriano Tocchi, Stefania Brozzetti, Low correspondence between K-ras mutations in pancreatic cancer tissue and detection of K-ras mutations in circulating DNA. Pancreas. ,vol. 32, pp. 171- 177 ,(2006) , 10.1097/01.MPA.0000202938.63084.E3